{"name":"Evotec","slug":"evotec","ticker":"EVT.DE","exchange":"XETRA","domain":"evotec.com","description":"Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.","hq":"Hamburg, Germany","founded":1993,"employees":"4788","ceo":"Christian Wojczewski","sector":"Drug Discovery CRO / Partnership Platform","stockPrice":4.63,"stockChange":0.16,"stockChangePercent":3.58,"marketCap":"$823M","metrics":{"revenue":780000000,"revenueGrowth":-11.4,"grossMargin":10.8,"rdSpend":0,"netIncome":-158980000,"cash":237268000,"dividendYield":0,"peRatio":-8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"EHT-0202 patent cliff ($1.2B at risk)","drug":"EHT-0202","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"EHT-1001 patent cliff ($500M at risk)","drug":"EHT-1001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Evotec reports Q4 2023 results","summary":"Evotec reported revenue of €1.4 billion for Q4 2023, beating analyst expectations.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Evotec partners with Pfizer on oncology research","summary":"Evotec and Pfizer announced a partnership to develop new oncology treatments.","drugName":"","sentiment":"positive"},{"date":"2023-08-22","type":"trial","headline":"Evotec's EHT-0202 shows promise in Phase 2 trial","summary":"Evotec's EHT-0202, a treatment for Alzheimer's disease, showed positive results in a Phase 2 trial.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOOEtsOEt1NlllVm84NlZiYzdoWjZWZVR4RUl0MGU4ZGc5elNyWGtSNW9EQ0t2Zm1WUFFYZl9tVzFMbUV4T09kWnpKWGdGTFJlRW96RTN1UXlhMFpaOTlVLWZOV01TTFlUQ0hhbzhVMkl1SU9GYTBuSjAyZWZ6TVVIYUYzcWdlNU5VVHZWSi1TdmtXNEd1YlVkeDEtNWtsRXdNX2FHUHdmZHFzTkZTbEl1QW1CdmRIdw?oc=5","date":"2026-04-07","type":"pipeline","source":"TradingView","summary":"Evotec Nominates Dieter Weinand as Supervisory Board Chairman - TradingView","headline":"Evotec Nominates Dieter Weinand as Supervisory Board Chairman","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxONlhicWFseDRFeXM1Wm5tV0ROZDNiOHVHeE1iNHhyNjNaQW9ZY29pREVya3JocWU0b3Y0aGZJLVJmQmU2b1pGSFFiOFc0ZG1XTzl3TUx2ckJwT281dUZkV3ZWRy1HZ2xxOHQ2VGJhRUV0SU1zeFFRY0tPeHJsMXY3RnBZSDA4MXMydEpZWDZENldyYzdLOE92WEpEcUdHUXNCNlpyMEZkcW5PZw?oc=5","date":"2026-03-19","type":"pipeline","source":"The Pharma Letter","summary":"Evotec, Bristol Myers take molecular glue candidate into clinic - The Pharma Letter","headline":"Evotec, Bristol Myers take molecular glue candidate into clinic","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"earnings","source":"simplywall.st","summary":"Evotec (XTRA:EVT) Valuation Check After Revenue Beat And New Horizon Transformation Plan - simplywall.st","headline":"Evotec (XTRA:EVT) Valuation Check After Revenue Beat And New Horizon Transformation Plan","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOWXNjMlBXX3ZfbnA4dXV4TUpmN3VNdVhOelJmRjdKVDdvbEluZ3lwaG9qNU1PNG4zZmxubzZ0Tllmb3BGa0FOaXRpc3Z0TnFReWFLZWdmZW1xOTduT3gzTU9UMmpINnlaLXZ2RWlzR0owbFB5Wlc1NE1MNXhTNTFtZ2xR?oc=5","date":"2026-01-11","type":"pipeline","source":"Yahoo Finance","summary":"Has The Recent Rebound In Evotec (XTRA:EVT) Reset Market Expectations? - Yahoo Finance","headline":"Has The Recent Rebound In Evotec (XTRA:EVT) Reset Market Expectations?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNaG51OEtMdDl1Y2hQV3c5SXdiZ0hhRDcwa3hWNTBWdS12dW04SDdTcjFXdGFlampQajQ4bmVsTDNFOEdxcmxjV0EyVEpDRjFXaU56NVhrRVhXVVl1eXRnRk9IQXRLNWdWRUFuYXhGTE5qYlpuMXMtRlVZYWNETUtycElNclVQMzgzbWs5a1BVTzlVLWd1MFl3bGtQS0lUN3BidkxRbC1oWkJNSzZ4STBwUTlCaXFVa1poZjZuUHd0RFVaVXZSVnc?oc=5","date":"2026-01-02","type":"pipeline","source":"AD HOC NEWS","summary":"Evotec SE: How a Quiet Drug Discovery Powerhouse Became a Platform Product in Biotech - AD HOC NEWS","headline":"Evotec SE: How a Quiet Drug Discovery Powerhouse Became a Platform Product in Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQdFdObk5sNHJIS2VUSTcwclhmVmVvc2NxNWRQcEJLbHpvQ1B3Qkx0REpia1d0YzhVd0ZaUG5fUGxQcDU0THpwTElNZlhxZks5ZmV6NmtEbU5EYTg4OGNmdlJtZS00azVpN05Sc0N5clN0OFdHMWFQZ3ZFYUZhSFRqS0o3bngwS3Nsck0wVzZyUWc?oc=5","date":"2025-11-11","type":"deal","source":"Yahoo Finance","summary":"Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - Yahoo Finance","headline":"Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Pa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFA3ek1wQVVPTUVBMkRRc2w0QlhCMmJxZW1Ibl9iV1owWHJvc0JMT0ZQN2lWV3VIZDdXdlBVYjNQQV8wVXpHbFhkd0xQelEtRG9iWGN4endnaXQwWTB4NTlJOFBvZU9PY2JRcDJXNUtXU3AyYU1UcDYySDRvNElHT0k?oc=5","date":"2025-11-06","type":"pipeline","source":"meyka.com","summary":"Evotec Stock Spikes Amidst Acquisition Rumors - meyka.com","headline":"Evotec Stock Spikes Amidst Acquisition Rumors","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-06","type":"earnings","source":"simplywall.st","summary":"Evotec (XTRA:EVT): Losses Deepen, Profitability Forecast to Return by 2027 Challenges Bearish View - simplywall.st","headline":"Evotec (XTRA:EVT): Losses Deepen, Profitability Forecast to Return by 2027 Challenges Bearish View","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNSEhkUVBidkpBSTllb2xBRE1ZeTBzTnBLMzZMbHZOZjJoNkp6bFlFaVp1MTBzQTVuNWcwQWZkWllpUlJXYkg5cHZtQXVqdFJvNjR3aTFtZG1od2I4RlU3cjdreUMydXBxdnV5SzJuT3MxeXRVdTZIeldaam96R01BWXZNQ3hGTFJ3Zy1aQV9ZQ1kwRlhnM0pDU2IzeDZ1a005alpMWV9B?oc=5","date":"2025-11-05","type":"deal","source":"The Pharma Letter","summary":"Sandoz finalizes deal to acquire Just-Evotec Biologics - The Pharma Letter","headline":"Sandoz finalizes deal to acquire Just-Evotec Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNTlhyYU45a1ByM3d1cWt0cU1TbTdkWF82bWQ4eGFhbHZCSlQ2dlQ2ajFIOUluR0JVbThwZ2w3Q1hTNWxPT3FpbjhiWUFqY19tazAyY1N6R0YxazZMUFZOcWpiYlZ0MmpyY0xXTUIzZG51Z2N3dVFMMGNQUlc5QmNjaDJ5WVJEVGYtZGNyUV9xNzg4UWREZXc?oc=5","date":"2025-04-17","type":"pipeline","source":"Fierce Biotech","summary":"Evotec axes 30% of assets as cost-cutting push hits pipeline - Fierce Biotech","headline":"Evotec axes 30% of assets as cost-cutting push hits pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOY1JiT0ZxU19hZ1Njc1A3U1pSd3J5R3IwM2NuLWpsRDUycXVGWW1fUURXRms0S2QzOXFLVVkycWdpTGZfVU91ZndYRGZrMU1scm5lUk4ya1h2ZFE0YzI5TU5OYWpHWmkzQm5aY3Fyd2o2ZUpOYlRlNWNlcy1LOTFHYzhNTFBiR3RDaTVVQ0U4eUFkZDZpQ2Z3U0pybl92VjgycEl1bkxtYnNrRlFBdE1PZmx1UFl4UQ?oc=5","date":"2024-11-15","type":"pipeline","source":"Bloomberg.com","summary":"Germany’s Evotec Gets Takeover Interest From Halozyme - Bloomberg.com","headline":"Germany’s Evotec Gets Takeover Interest From Halozyme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNLU1JbEJjRXc0UnliSTkxZmJlbVR5UTVfdzV5ZjcwU2p1ZHllLVd3Z196c05XRHhBejYxR0F5MHpsNlktS0pSMjd6a1pZYVhUM3JJa0Y4QmJSbm9tRjFDdEdOVzJ1VVBvTVpDTDlPR18ydjVRSlR5X2pZYkt6TVN6MmlxMzBVekE?oc=5","date":"2024-11-15","type":"pipeline","source":"MedCity News","summary":"Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec - MedCity News","headline":"Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec","sentiment":"neutral"}],"patents":[{"drugName":"EHT-1001","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"EU","annualRevenue":500000000},{"drugName":"EHT-0202","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Charles River Laboratories","IQVIA","Parexel"],"therapeuticFocus":["Oncology","Neurology","Infectious Diseases"],"financials":null,"yahoo":{"currentPrice":4.63,"previousClose":4.47,"fiftyTwoWeekHigh":8.57,"fiftyTwoWeekLow":4,"fiftyTwoWeekRange":"3.995 - 8.566","fiftyDayAverage":5.32,"twoHundredDayAverage":5.99,"beta":1.24,"enterpriseValue":1041535296,"forwardPE":-8,"priceToBook":1.03,"priceToSales":1.09,"enterpriseToRevenue":1.38,"enterpriseToEbitda":80118.1,"pegRatio":0,"ebitda":13000,"ebitdaMargin":0,"freeCashflow":-207618880,"operatingCashflow":1410000,"totalDebt":484616992,"debtToEquity":60.6,"currentRatio":2.12,"returnOnAssets":-2.7,"returnOnEquity":-18,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":6,"targetMeanPrice":6.92,"targetHighPrice":10,"targetLowPrice":4.4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10,"institutionHeldPercent":61.5,"sharesOutstanding":177746121,"floatShares":132250674,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.9,"epsForward":-0.58,"revenuePerShare":4.26,"bookValue":4.5,"officers":[{"age":52,"name":"Dr. Christian  Wojczewski Ph.D.","title":"CEO & Management Board Member"},{"age":61,"name":"Dr. Cord  Dohrmann Ph.D.","title":"Chief Scientific Officer & Member of Management Board"},{"age":48,"name":"Ms. Aurelie  Dalbiez","title":"Chief People Officer & Member of Management Board"},{"age":49,"name":"Mr. Paul  Hitchin","title":"CFO & Member of Management Board"},{"age":null,"name":"Dr. Sarah  Fakih","title":"Executive VP, Head of Global Communications & Investor Relations"},{"age":54,"name":"Dr. Christian  Dargel","title":"EVP Global Head of Legal & Compliance"},{"age":75,"name":"Dr. Ian M. Hunneyball","title":"Senior Vice President of Programme Management & Clinical Operations"},{"age":null,"name":"Dr. David  Hallet","title":"Executive Vice President"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.evotec.com","phone":"49 40 560 81 0"}}